These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Limited sampling strategy for cyclosporine (Neoral) area under the curve monitoring in pediatric kidney transplant recipients. Strong DK, Lai A, Primmett D, White CT, Lirenman DS, Carter JE, Hurley RM, Virji M, Ensom MH. Pediatr Transplant; 2005 Oct; 9(5):566-73. PubMed ID: 16176411 [Abstract] [Full Text] [Related]
6. Investigation of the pharmacokinetics of cyclosporine in patients following long-term administration after a kidney transplant: comparison of Neoral and Sandimmune. Takahara S, Ichimaru N, Kojima Y, Namba Y, Toki K, Shi Y, Yoshimura K, Matsumiya K, Nonomura N, Okuyama A. Transplant Proc; 2004 Mar; 36(2 Suppl):456S-460S. PubMed ID: 15041387 [Abstract] [Full Text] [Related]
7. Monitoring C2 level predicts exposure in maintenance lung transplant patients receiving the microemulsion formulation of cyclosporine (Neoral). Jaksch P, Kocher A, Neuhauser P, Sarahrudi K, Seweryn J, Wisser W, Klepetko W. J Heart Lung Transplant; 2005 Aug; 24(8):1076-80. PubMed ID: 16102443 [Abstract] [Full Text] [Related]
8. Evolution of the therapeutic drug monitoring of cyclosporine. Citterio F. Transplant Proc; 2004 Mar; 36(2 Suppl):420S-425S. PubMed ID: 15041378 [Abstract] [Full Text] [Related]
9. Correlation Between C2 and AUC(0-4) in Renal Transplant Patients Treated With Diltiazem. Aros CA, Schneider HO, Flores CA, Ardiles LG, Alruiz PA, Jerez V, Mezzano SA. Transplant Proc; 2005 Apr; 37(3):1580-2. PubMed ID: 15866679 [Abstract] [Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic. Brunet M, Crespo M, Millán O, Serón D, Torregrosa V, Jiménez O, Moreso F, Martorell J, Grinyo JM, Oppenheimer F. Transplant Proc; 2007 Sep; 39(7):2160-2. PubMed ID: 17889124 [Abstract] [Full Text] [Related]
14. C2 is an age-independent parameter for optimal cyclosporine exposure in long-term kidney transplant recipients. Ferraresso M, Citterio F, Ghio L, Romagnoli J, Edefonti A, Berardinelli L, Castagneto M. Transplant Proc; 2004 Nov; 36(9):2656-8. PubMed ID: 15621115 [Abstract] [Full Text] [Related]
15. Two-hour postdose concentration: a reliable marker for cyclosporine exposure in adolescents with stable renal transplants. John U, Ullrich S, Roskos M, Misselwitz J. Transplant Proc; 2005 Apr; 37(3):1608-11. PubMed ID: 15866686 [Abstract] [Full Text] [Related]
17. A limited sampling strategy for the estimation of 12-hour cyclosporine neoral area under the curve in Chinese cardiac transplant recipients. Wang CH, Ko WJ, Chou NK, Wang SS. Transplant Proc; 2004 Oct; 36(8):2390-2. PubMed ID: 15561259 [Abstract] [Full Text] [Related]
18. Clinical benefits of neoral C2 monitoring in the long-term management of renal transplant recipients. Cole E, Maham N, Cardella C, Cattran D, Fenton S, Hamel J, O'Grady C, Smith R. Transplantation; 2003 Jun 27; 75(12):2086-90. PubMed ID: 12829917 [Abstract] [Full Text] [Related]
19. Hepatotoxicity associated with cyclosporine monitoring using C2 recommendations in adults renal recipients receiving ketoconazole. Videla C, Vega J, Borja H. Transplant Proc; 2005 Apr 27; 37(3):1574-6. PubMed ID: 15866677 [Abstract] [Full Text] [Related]